Amneal Pharmaceuticals in Ireland

Clinical Trials sponsored by Amneal Pharmaceuticals

About Amneal Pharmaceuticals

Amneal's Generics Division focuses on a broad range of therapeutic areas, including solid oral dosage products and alternative dosage form products. The company's Specialty Pharma Division is focused on the development of proprietary branded pharmaceutical products for the treatment of Central Nervous System disorders, Endocrine disorders and other select specialty segments. This division commercializes several branded pharmaceutical products, including Rytary, an extended release oral capsule formulation for the treatment of Parkinson's disease, Unithroid, for treatment of hypothyroidism, Emverm, for treatment of certain gastrointestinal infections, and Zomig Nasal Spray, for the acute treatment of migraines. As of July 2019, the company owned ten manufacturing sites and seven R&D sites in the United States, Ireland and India. In 2020, in response to the interest in chloroquine and hydroxychloroquine during the COVID-19 pandemic, and before the United States Food and Drug Administration's emergency use authorization was withdrawn, Amneal ramped up production. In June 2023, the US FDA declined to approve a drug (carbidopa-levodopa) designed to help control symptoms in Parkinson's disease patients for a longer duration, because of inadequate safety data